FDA Approves New Combination Treatment for Acute Myeloid Leukemia

April 28, 2017 – The U.S. Food and Drug Administration today approved midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3, in combination with chemotherapy. The drug is approved for use with a companion diagnostic, the LeukoStrat CDx FLT3 Mutation Assay, which is used to detect the FLT3 mutation in patients with AML. AML is a rapidly progressing cancer … (leggi tutto)